Single-agent immune checkpoint inhibitors (ICIs) represented by programmed cell death 1(PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been recently evaluated in HCC patients, and the results of clinical trials were disappointed [16–18]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.